Laura L.  Brocklehurst net worth and biography

Laura Brocklehurst Biography and Net Worth

Insider of Surgery Partners
Laura Brocklehurst has served as Chief Human Resources Officer of Surgery Partners since June 2019. Prior to this, she served as the Chief Human Resources Officer for Surgery Partners, Inc. She joined Surgery Partners in 2018, and prior to this served as Sr. Director, HR Business Partner at SC Johnson from 2013 to 2018 for their Product Supply organization and then Latin America business. From 2006 to 2013 she held HR leadership positions with Healthways, Inc., a health and well-being company.

What is Laura L. Brocklehurst's net worth?

The estimated net worth of Laura L. Brocklehurst is at least $1.03 million as of November 9th, 2022. Ms. Brocklehurst owns 41,424 shares of Surgery Partners stock worth more than $1,029,801 as of April 25th. This net worth approximation does not reflect any other investments that Ms. Brocklehurst may own. Learn More about Laura L. Brocklehurst's net worth.

How do I contact Laura L. Brocklehurst?

The corporate mailing address for Ms. Brocklehurst and other Surgery Partners executives is 310 Seven Springs Way Suite 500, Brentwood TN, 37027. Surgery Partners can also be reached via phone at (615) 234-5900 and via email at [email protected]. Learn More on Laura L. Brocklehurst's contact information.

Has Laura L. Brocklehurst been buying or selling shares of Surgery Partners?

Laura L. Brocklehurst has not been actively trading shares of Surgery Partners during the last ninety days. Learn More on Laura L. Brocklehurst's trading history.

Who are Surgery Partners' active insiders?

Surgery Partners' insider roster includes Jennifer Baldock (Insider), Harrison Bane (President of the American Group), Marissa Brittenham (Chief Strategy Officer), Laura Brocklehurst (Insider), Danielle Burkhalter (Chief Human Resources Officer), Thomas Cowhey (CFO), Teresa DeLuca (Director), Wayne DeVeydt (Chairman), David Doherty (CFO), Jason Evans (CEO), George Goodwin (Insider), Andrew Kaplan (Director), Bradley Owens (National Group President), Anthony Taparo (Insider), and Brent Turner (Director). Learn More on Surgery Partners' active insiders.

Are insiders buying or selling shares of Surgery Partners?

During the last twelve months, insiders at the sold shares 15 times. They sold a total of 8,031,894 shares worth more than $268,619,881.64. The most recent insider tranaction occured on March, 13th when CEO Jason Eric Evans sold 4,840 shares worth more than $143,796.40. Insiders at Surgery Partners own 2.6% of the company. Learn More about insider trades at Surgery Partners.

Information on this page was last updated on 3/13/2024.

Laura L. Brocklehurst Insider Trading History at Surgery Partners

See Full Table

Laura L. Brocklehurst Buying and Selling Activity at Surgery Partners

This chart shows Laura L. Brocklehurst's buying and selling at Surgery Partners by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Surgery Partners Company Overview

Surgery Partners logo
Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy, and wound care; and ancillary services, including multi-specialty physician practices, urgent care facilities, and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
Read More

Today's Range

Now: $24.84
Low: $24.53
High: $25.47

50 Day Range

MA: $28.88
Low: $23.42
High: $34.70

2 Week Range

Now: $24.84
Low: $22.05
High: $45.79

Volume

639,830 shs

Average Volume

901,445 shs

Market Capitalization

$3.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.71